{
    "organizations": [],
    "uuid": "d89c0752ccd55c56d84ae38fa7d075e80bafab3d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/us-samsung-bioepis-stocks-samsung-c-t-co/samsung-ct-shares-rise-after-report-of-planned-stake-purchase-in-biopharma-affiliate-idUSKBN1HH00Y",
    "ord_in_thread": 0,
    "title": "Samsung C&T says no plan currently to buy a stake in biopharma affiliate",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "SEOUL (Reuters) - Samsung C&T Corp ( 028260.KS ) said on Tuesday it has no plan currently to purchase shares in Samsung Bioepis Co, after a report said the company is considering raising up to 3 trillion won ($2.8 billion) to buy a 30 percent stake in its biopharma affiliate.\nFILE PHOTO: Employees are reflected on a logo of Samsung C&T Corp at the company's headquarters in Seoul, South Korea, July 16, 2015. REUTERS/Kim Hong-Ji “Samsung C&T is reviewing various measures to secure growth engine for the future, but the firm is not planning at the moment to buy a stake in Samsung Bioepis,” Samsung C&T said in a statement.\nReporting by Haejin Choi; Editing by Hyunjoo Jin; Editing by Muralikumar Anantharaman\n ",
    "published": "2018-04-10T08:21:00.000+03:00",
    "crawled": "2018-04-10T09:25:37.031+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "seoul",
        "reuters",
        "samsung",
        "c",
        "corp",
        "said",
        "tuesday",
        "plan",
        "currently",
        "purchase",
        "share",
        "samsung",
        "bioepis",
        "co",
        "report",
        "said",
        "company",
        "considering",
        "raising",
        "trillion",
        "billion",
        "buy",
        "percent",
        "stake",
        "biopharma",
        "affiliate",
        "file",
        "photo",
        "employee",
        "reflected",
        "logo",
        "samsung",
        "c",
        "corp",
        "company",
        "headquarters",
        "seoul",
        "south",
        "korea",
        "july",
        "samsung",
        "c",
        "reviewing",
        "various",
        "measure",
        "secure",
        "growth",
        "engine",
        "future",
        "firm",
        "planning",
        "moment",
        "buy",
        "stake",
        "samsung",
        "bioepis",
        "samsung",
        "c",
        "said",
        "statement",
        "reporting",
        "haejin",
        "choi",
        "editing",
        "hyunjoo",
        "jin",
        "editing",
        "muralikumar",
        "anantharaman"
    ]
}